repetitive seizures in patients with epilepsy. In December 2007, Jazz
Pharmaceuticals dosed the first patient in a Phase II clinical trial of
-- A single dose pharmacokinetic study of a controlled-release formulation
of JZP-4, a product candidate for the treatment of partial epilepsy and
bipolar disorder, was completed in the fourth quarter of 2007, and
Phase II clinical trial activities are underway.
Jazz Pharmaceuticals will be hosting an Investor Day on March 13, 2008 beginning at 10:00 a.m. Eastern Time/7:00 a.m. Pacific Time. The event will include presentations by Jazz Pharmaceuticals executives and by Dr. Mark H. Pollack, a noted psychiatrist at Massachusetts General Hospital and Professor at Harvard Medical School, who will speak about obsessive compulsive disorder and social anxiety disorder. The event will be available by live audio webcast, and the accompanying presentation materials will also be available on the investor relations section of Jazz Pharmaceuticals' web site at http://www.JazzPharmaceuticals.com.
Jazz Pharmaceuticals will host an investor conference call and live
audio webcast to discuss its financial results and provide a business
update on its commercial and development activities on February 13, 2008
commencing at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The live
webcast may be accessed on Jazz Pharmaceuticals' website at
http://www.JazzPharmaceuticals.com. Please connect to the website prior to
the start of the conference call to ensure adequate time for any software
downloads that may be necessary. An archived version of the webcast will be
available through February 27, 2008. Investors may participate in the
conference call by dialing 1-800-299-0148 in the U.S., or 1-617-801-9711
outside the U.S., and entering
|SOURCE Jazz Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved